1-4 of 4
Carmelo Carlo-Stella
Close
Sort by
Journal Articles

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Clinical Trials & Observations
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Ai, Melhem Solh, Kirit M. Ardeshna, Brian Hess, Paolo F. Caimi, Anastasios Stathis, Carmelo Carlo-Stella, Juan Pablo Alderuccio, Brad Kahl, Ying Wang, Yajuan Qin, Zhiying Cindy Xu, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2023) 8 (1): 93–98.
https://doi.org/10.1182/bloodadvances.2023010636
Published: 2023
Includes: Supplemental data
Journal Articles

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Clinical Trials & Observations
Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4736–4739.
https://doi.org/10.1182/bloodadvances.2022007782
Published: 2022
Journal Articles

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Bicky Thapa, Paolo F. Caimi, Kirit M. Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S. Kahl, Mehdi Hamadani
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3850–3852.
https://doi.org/10.1182/bloodadvances.2020002587
Published: 2020
Journal Articles

Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Manuela Zanni, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Francesca Ricci, Carmelo Carlo-Stella
Journal: Blood Advances
Blood Adv (2020) 4 (1): 136–140.
https://doi.org/10.1182/bloodadvances.2019000984
Published: 2020
Includes: Supplemental data